PE20221759A1 - Nuevos analogos de il-2 inmunoestimuladores - Google Patents

Nuevos analogos de il-2 inmunoestimuladores

Info

Publication number
PE20221759A1
PE20221759A1 PE2022001948A PE2022001948A PE20221759A1 PE 20221759 A1 PE20221759 A1 PE 20221759A1 PE 2022001948 A PE2022001948 A PE 2022001948A PE 2022001948 A PE2022001948 A PE 2022001948A PE 20221759 A1 PE20221759 A1 PE 20221759A1
Authority
PE
Peru
Prior art keywords
immunostimulators
new analogues
interleukin
analogues
new
Prior art date
Application number
PE2022001948A
Other languages
English (en)
Inventor
Euh Lim Oh
Sang Yun Kim
Yong Ho Heo
Jin Young Kim
Cho Rong Park
Jun Sub Park
Hyun Soo Ryu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20221759A1 publication Critical patent/PE20221759A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a cambios en los receptores alfa de interleucina 2 y analogos de interleucina 2 con mayor afinidad de union por los receptores beta de interleucina 2
PE2022001948A 2020-03-31 2021-03-31 Nuevos analogos de il-2 inmunoestimuladores PE20221759A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200039476 2020-03-31
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Publications (1)

Publication Number Publication Date
PE20221759A1 true PE20221759A1 (es) 2022-11-11

Family

ID=77930406

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001948A PE20221759A1 (es) 2020-03-31 2021-03-31 Nuevos analogos de il-2 inmunoestimuladores

Country Status (16)

Country Link
US (2) US11746137B2 (es)
EP (1) EP4130027A4 (es)
JP (2) JP2023515247A (es)
KR (2) KR102545250B1 (es)
CN (2) CN115427437B (es)
AR (1) AR121713A1 (es)
AU (2) AU2021202825B2 (es)
BR (1) BR112022018730A2 (es)
CA (1) CA3169564A1 (es)
CL (1) CL2022002562A1 (es)
IL (1) IL295826A (es)
MX (1) MX2022011893A (es)
PE (1) PE20221759A1 (es)
TW (1) TW202204387A (es)
WO (1) WO2021201615A1 (es)
ZA (1) ZA202209565B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
TW202413442A (zh) * 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) * 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
EP0378666A4 (en) * 1988-07-05 1992-01-22 Amgen Inc. Interleukin ii analogs
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
WO2001024814A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2005227263A1 (en) * 2004-03-05 2005-10-06 Novartis Vaccines And Diagnostics, Inc. In vitro test system for predicting patient tolerability of therapeutic agents
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2655409A4 (en) * 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
EP3616727B1 (en) 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
TWI749433B (zh) 2014-10-21 2021-12-11 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
EP3589373A4 (en) * 2017-03-03 2020-12-23 Obsidian Therapeutics, Inc. COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
CA3067909A1 (en) * 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2019057180A1 (en) * 2017-09-25 2019-03-28 Dingfu Biotarget Co., Ltd. PROTEIN HETÉRODIMÈRE AND USE THEREOF
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112105632A (zh) 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
CN113840832A (zh) * 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
JP2021528105A (ja) * 2018-06-22 2021-10-21 キュージーン インコーポレイテッドＣｕｇｅｎｅ Ｉｎｃ． インターロイキン−２バリアントおよびその使用方法
CN112771072A (zh) * 2018-07-24 2021-05-07 生物技术Rna制药有限公司 Il2激动剂
PE20201418A1 (es) * 2018-09-17 2020-12-09 Gi Innovation Inc Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
WO2020102501A1 (en) * 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114478743A (zh) 2019-12-17 2022-05-13 北京志道生物科技有限公司 白介素-2衍生物
AU2021231869A1 (en) 2020-03-05 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University Designed IL-2 variants

Also Published As

Publication number Publication date
TW202204387A (zh) 2022-02-01
AR121713A1 (es) 2022-06-29
EP4130027A4 (en) 2024-08-14
US20230124171A1 (en) 2023-04-20
KR20230088656A (ko) 2023-06-20
MX2022011893A (es) 2022-10-18
KR20210122200A (ko) 2021-10-08
CN115427437B (zh) 2024-04-19
JP2024041747A (ja) 2024-03-27
AU2021202825B2 (en) 2022-06-30
JP2023515247A (ja) 2023-04-12
US20230348550A1 (en) 2023-11-02
KR102545250B1 (ko) 2023-06-21
AU2022203841A1 (en) 2022-06-23
CN118271419A (zh) 2024-07-02
AU2021202825A1 (en) 2021-10-14
BR112022018730A2 (pt) 2022-11-01
CL2022002562A1 (es) 2023-03-17
US11746137B2 (en) 2023-09-05
WO2021201615A1 (ko) 2021-10-07
ZA202209565B (en) 2023-12-20
EP4130027A1 (en) 2023-02-08
CA3169564A1 (en) 2021-10-07
CN115427437A (zh) 2022-12-02
IL295826A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
PE20221759A1 (es) Nuevos analogos de il-2 inmunoestimuladores
CL2023002504A1 (es) Novedoso conjugado de análogo de il-2 inmunoestimulante y procedimiento de preparación del mismo
AR114445A1 (es) Conjugados de il-15, y sus usos
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
DOP2024000020A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana
CL2023001747A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
CL2023001745A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
ECSP23087684A (es) Compuestos y métodos dirigidos a la epirregulina
FR358981A (fr) Perfectionnements apportés aux corsets
AR117300A1 (es) Análogos de insulina con afinidad de unión al receptor de insulina reducida
JP1781951S (ja) 刷毛
TWD227429S (zh) 原子筆
JP1765113S (ja) かかとパッド
JP1754174S (ja) マーカーペンの芯支持具
BR112023000117A2 (pt) Composição
UY39471A (es) Novedosos análogos de glutamina
ECSDI21014446S (es) Férulas caninas
FR477491A (fr) Perfectionnements aux mines et aux corps submersibles analogues
CL2020003404A1 (es) Tolva que contiene extensión deformable
FR474083A (fr) Perfectionnements aux protèges-pointes pour épingles à chapeaux et leurs analogues
FR458784A (fr) Perfectionnements apportés aux cordons conducteurs pour tableaux de distribution et autres usages analogues
FR417994A (fr) Perfectionnements apportés aux billards démontables
FR341734A (fr) Perfectionnements apportés aux corsets
CH62936A (fr) Mécanisme de distribution aux moteurs à piston
FR460692A (fr) Perfectionnements apportés aux queues de billards